US 12,453,819 B2
Injector
Michael Travanty, S. Minneapolis, MN (US); and Steven W. Mattix, Golden Valley, MN (US)
Assigned to Antares Pharma, Inc., Ewing, NJ (US)
Appl. No. 17/262,676
Filed by Antares Pharma, Inc., Ewing, NJ (US)
PCT Filed Jul. 24, 2019, PCT No. PCT/US2019/043281
§ 371(c)(1), (2) Date Jan. 22, 2021,
PCT Pub. No. WO2020/036717, PCT Pub. Date Feb. 20, 2020.
Claims priority of provisional application 62/702,661, filed on Jul. 24, 2018.
Prior Publication US 2021/0308380 A1, Oct. 7, 2021
Int. Cl. A61M 5/20 (2006.01); A61K 31/485 (2006.01); A61M 5/32 (2006.01)
CPC A61M 5/2053 (2013.01) [A61K 31/485 (2013.01); A61M 5/3202 (2013.01); A61M 5/326 (2013.01)] 26 Claims
OG exemplary drawing
 
1. An injector, comprising:
a housing;
a cap detachably coupled to the housing;
a medicament container including a medicament comprising about 1.1 mg/mL naloxone HCl dihydrate, about 1 mg/mL methionine, and a pharmaceutically acceptable carrier wherein the medicament after storage at 25° C. for 2 to 9 months has between 0.12% and 0.81% impurities;
a ram assembly having a ram configured to pressurize the medicament container for expelling the medicament therefrom, the ram assembly including a trigger engagement member;
an energy source associated with the ram for powering the ram to expel medicament from the medicament container;
a trigger member disposed about an axis, the trigger member moveable between a pre-firing configuration and a firing configuration, wherein medicament is expelled from the medicament container when the trigger member is in the firing configuration; and
a needle guard moveably coupled to the housing, the needle guard movable between a storage position and a pre-injection position,
wherein the needle guard moves from the storage position to the pre-injection position as the cap is detached from the housing.